SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Michael Anthony who wrote (282)3/7/1998 8:54:00 PM
From: Zeev Hed  Read Replies (1) | Respond to of 1321
 
Michael, for some reasons it works, so far on only 42% of the test subjects and so far only for "metastazed" melanoma. It is not as straightforward, since in most cases it requires the use of Interleukin2 to beef up the immune system to fight the cancer. Yet, it is quite promising.

Zeev



To: Michael Anthony who wrote (282)3/8/1998 5:03:00 PM
From: alexander orlov  Read Replies (1) | Respond to of 1321
 
a small co named immune therapy corp recently aquired by antivirals
(AVII) has a very interesting and a intriguing cancer vaccine.they are in phase III trials for colorectal ca..this could be huge..a larger canadian co named biomira (biomf) has a vaccine in PH> III trials for breast ca.. both use what you brought up in earlier post. for more read on avii thread
ao


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News